Nedosiran
Nedosiran (DCR-PHXC) is an RNA interference (RNAi) targeting lactate dehydrogenase (LDH) . Nedosiran represents an impactful potential therapeutic for primary hyperoxaluria (PH) with end-stage renal disease (ESRD) . Nedosiran is a GalNAc-dsRNA conjugate[1][2][3].
Product Specifications
CAS Number
2266591-83-5
Product Name Alternative
DCR-PHXC
UNSPSC
12352208
Target
Lactate Dehydrogenase; Small Interfering RNA (siRNA)
Type
Oligonucleotides
Related Pathways
Epigenetics; Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease
Assay Protocol
https://www.medchemexpress.com/nedosiran.html
Solubility
10 mM in H2O
Smiles
[Nedosiran]
Molecular Formula
C662H865F19N231O413P57S6
Molecular Weight
20985.12
References & Citations
[1]Kevin Shee, et al. Nedosiran Dramatically Reduces Serum Oxalate in Dialysis-Dependent Primary Hyperoxaluria 1: A Compassionate Use Case Report. Urology.2021 Oct;156:e147-e149.|[2]Gema Ariceta, et al. Hepatic Lactate Dehydrogenase A: An RNA Interference Target for the Treatment of All Known Types of Primary Hyperoxaluria. Kidney Int Rep. 2021 Feb 3;6 (4) :1088-1098. |[3]Thomas A Forbes, et al. Therapeutic RNA interference: A novel approach to the treatment of primary hyperoxaluria. Br J Clin Pharmacol. 2021 May 22.
Shipping Conditions
Room temperature
Scientific Category
Oligonucleotides
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
MBS6273046-01 0.1 mL
ALOXE3, ID (ALOXE3, Epidermis-type lipoxygenase 3) (MaxLight 750)
Sign In for Pricing
View Details MBS6273046-02 5x 0.1 mL
ALOXE3, ID (ALOXE3, Epidermis-type lipoxygenase 3) (MaxLight 750)
Sign In for Pricing
View Details 